莫罗尼西德在糖尿病脏病中减弱细胞脂沉积:一个网络药理学,分子对接和实验验证研究
Yao Chen1, Ming Chen1, Wenhui Zhu1
1Renal Division, Department of Medicine, Heilongjiang Academy of Chinese Medicine Sciences, Harbin, China.
International immunopharmacology
|July 3, 2024
概括
莫罗尼西德 (MOR) 通过调节 podocytes 中的脂质代谢来改善糖尿病病 (DN). 它针对PGC-1α通路来控制胆固醇的排放和摄入,减少脏中的脂质沉积.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 代谢疾病 代谢疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病病 (DN) 的进展与不调节的脂质代谢有关.
- 莫罗尼西德 (MOR),来自Cornus officinalis,此前改善了管状脂沉积.
- 这项研究研究了MOR对细胞脂质沉积和DN机制的影响.
研究的目的:
- 为了确定MOR是否可以改善DNA中的podocyte脂质沉积.
- 阐明MOR减少DN的分子机制.
- 确定参与MOR治疗效果的关键信号通路.
主要方法:
- 网络药理学和生物信息学预测了MOR在DN脂质代谢中的目标.
- 分子对接评估了MOR与关键蛋白质的结合亲和力.
- 在体内和体外实验 (细胞试验,动物模型) 验证了预测的目标和途径.
主要成果:
- 在DNA中,MOR的点是PGC-1α,LXRs,ABCA1,PPARY,CD36和nephrin.
- MOR直接与PGC-1α结合,这是下游脂质代谢蛋白的关键调节者.
- MOR治疗增加了PGC-1α,PPARY,ABCA1和尼林的表达,同时降低了podocytes中的CD36,证实了其治疗作用.
结论:
- MOR通过调节 podocyte 脂质代谢来改善 DN.
- MOR通过PGC-1α/LXRs/ABCA1通路来调节胆固醇的外流.
- MOR通过PGC-1α/PPARY/CD36途径控制胆固醇摄入量,减少脏脂质沉积.
更多相关视频
05:58Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
158
07:38Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
8.4K
相关概念视频
01:22Heart Failure Drugs: Diuretics
362
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
362
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
511
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
511
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
01:16Antihypertensive Drugs: Action of Diuretics
665
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
665
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
595
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
595
01:23Dipeptidyl Peptidase 4 Inhibitors
180
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
180